Miscellaneous
HbA1c is the traditional primary metric for glycemia, but as a measure of average glycemia over 3 months, how much does it really tell us about glycemic control? Should we be assessing shorter-term glycemic variability and long-term fluctuations in HbA1c? Join Dr Irl Hirsch for a discussion of how this may improve patient outcomes. We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. References: Bedenis R et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014 Dec;37(12):3301-8 Bonds D et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010 Jan;340 Davis S et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care. 2019 Jan; 42(1):157-163 Zinman B et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018 Jan;61(1):48-57 Cardoso C et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018; 17: 33 Gorst C et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care 2015 Dec; 38(12): 2354-2369 Perlman JE, et al. HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis. Diabetes Technol Ther. 2021 Apr;23(4):253-258. Disclosures: Dr Irl Hirsch declares no relevant financial relationships within the past 12 months. Funding statement: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.